BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Catalyst Brief//FDA catalyst calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Catalyst Brief — FDA catalyst calendar
REFRESH-INTERVAL;VALUE=DURATION:PT6H
X-PUBLISHED-TTL:PT6H
BEGIN:VEVENT
UID:event-103@catalystbrief.girapphe.com
DTSTAMP:20261117T121556Z
LAST-MODIFIED:20261117T121556Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:Readout: Amgen — Maridebart Cafraglutide [Jan 2027]
DESCRIPTION:Phase 3 primary completion: Evaluation of Maridebart Cafragluti
 de in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity
  or Are Overweight.\nSource: https://clinicaltrials.gov/study/NCT06858839\
 nhttps://catalystbrief.girapphe.com/e/103?lang=en\nNot investment advice. 
 Dates may change.
URL:https://catalystbrief.girapphe.com/e/103?lang=en
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
